A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Mongersen GED-0301 Maintenance Therapy in Subjects With Crohn's Disease
Phase of Trial: Phase III
Latest Information Update: 13 Apr 2018
At a glance
- Drugs Mongersen (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Registrational
- Acronyms SUSTAIN
- Sponsors Celgene Corporation
- 08 Mar 2018 This study has been completed in Belgium.
- 31 Jan 2018 This trial has been completed in Sweden (end date: 2017-10-19) according to European Clinical Trials Database record.
- 27 Jan 2018 This trial has been completed in Greece (end date: 2018-01-04)